Company intelligence / Profile preview

Aveta Biomics

Bedford, Massachusetts, United Statesavetabiomics.com ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

Aveta Biomics is developing first-in-class immune-oncology drugs using a platform inspired by evolutionary biology. Their approach aims to address tumor heterogeneity and prevent drug resistance. Lead programs have reached Phase 2 clinical trials in glioblastoma and head & neck squamous cell carcinoma. The company emphasizes durable response, safety, and prevention of both primary malignancies in high-risk populations and recurrences in treated patients.[1][4][5]

Therapeutic areas: Oncology
Modalities: Small molecules[5]Polypharmaceutical drug compositions (combination therapies)[1][4]
Industry: Biotech

Drug pipeline

3 assets

APG-157

2 more assets in the full pipeline.

Request access →

Partnerships

University of Miami (clinical trial collaboration)[5]No major pharmaceutical partnerships publicly disclosed as of May 2025.

Beyond the preview

Go deeper on Aveta Biomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aveta Biomics.

Explore the full profile